Reviva Pharmaceuticals’ Schizophrenia Candidate Shows Favorable Drug-Drug Interaction Data
Reviva Pharmaceuticals Holdings Inc (NASDAQ:RVPH) has announced data from its clinical drug-drug interaction (DDI) study investigating the potential effect of CYP3A4…